20 December, 2021 by The TZ Newswire Staff Comments Off on Aptose Provides Update on APTO-253 Program
Aptose Provides Update on APTO-253 Program
— Clinical development of the MYC repressor APTO-253 will be discontinued —
— Company will focus on advancing kinome inhibitor pipeline —
20 December, 2021 by The TZ Newswire Staff Comments Off on Cytokinetics and JI XING Announce Expansion of Collaboration to Include Licensing of Omecamtiv Mecarbil in China; RTW to Add to Its Investment in Cytokinetics
Cytokinetics and JI XING Announce Expansion of Collaboration to Include Licensing of Omecamtiv Mecarbil in China; RTW to Add to Its Investment in Cytokinetics
JI XING to Develop and Commercialize
Novel Cardiac Myosin Activator in Patients with Heart Failure
20 December, 2021 by The TZ Newswire Staff Comments Off on VBL Therapeutics Selected for €17.5 Million of Funding from Horizon Europe EIC Accelerator Program
VBL Therapeutics Selected for €17.5 Million of Funding from Horizon Europe EIC Accelerator Program
VBL is among only 9% of companies across industries selected by the EIC Accelerator